RCMI Coordinating Center (RCMI CC) Header Logo

Recombinant human lactoferrin carrying humanized glycosylation exhibits antileukemia selective cytotoxicity, microfilament disruption, cell cycle arrest, and apoptosis activities.

Nakamura-Bencomo S, Gutierrez DA, Robles-Escajeda E, Iglesias-Figueroa B, Siqueiros-Cend?n TS, Espinoza-S?nchez EA, Ar?valo-Gallegos S, Aguilera RJ, Rasc?n-Cruz Q, Varela-Ramirez A. Recombinant human lactoferrin carrying humanized glycosylation exhibits antileukemia selective cytotoxicity, microfilament disruption, cell cycle arrest, and apoptosis activities. Invest New Drugs. 2021 04; 39(2):400-415.

View in: PubMed

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support